Clinical Trial Update: A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of ALN-TTR02 in Japanese healthy volunteers; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• ALN-TTR02 (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin (TTR)-Mediated Amyloidosis | Phase 1 | Status: COMPLETED